Reaction

Near Death Experience reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,223 reports · 59 co-occurring drugs

As of the last recalculation, Near Death Experience appears in 3,223 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 13.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Niraparib	45	13.3	13.3
Hydrocodone Bitartrate And Acetaminophen	73	8.5	8.5
Fremanezumab-Vfrm	15	8.5	8.5
Sacubitril And Valsartan	135	7.8	7.8
Dutasteride	8	6.4	6.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	10	6.2	6.2
Oral Semaglutide	68	6.1	6.1
Glatiramer Acetate	54	5.9	5.9
Lanreotide Acetate	7	5.8	5.8
Ravulizumab	12	5.8	5.8
Tafamidis	10	5.5	5.5
Thyroid, Porcine	9	5.5	5.5
Oxycodone Hydrochloride	167	5.2	5.2
Hydromorphone Hydrochloride	67	4.8	4.8
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	30	4.7	4.7
Naltrexone Hydrochloride And Bupropion Hydrochloride	6	4.6	4.6
Alpelisib	6	4.5	4.5
Lurasidone Hydrochloride	14	4.3	4.3
Umeclidinium	6	4.3	4.3
Nirmatrelvir And Ritonavir	36	4.3	4.3
Lisdexamfetamine Dimesylate	22	4.3	4.3
Tiotropium Bromide Inhalation Spray	7	4.0	4.0
Buprenorphine Hydrochloride, Naloxone Hydrochloride	14	3.8	3.8
Dofetilide	6	3.7	3.7
Imatinib	10	3.7	3.7
Siponimod	5	3.6	3.6
Bosutinib	5	3.6	3.6
Benralizumab	11	3.6	3.6
Cladribine	5	3.4	3.4
Paliperidone	12	3.3	3.3
Empagliflozin	34	3.3	3.3
Ribociclib	16	3.3	3.3
Morphine Sulfate	60	3.2	3.2
Ofatumumab	16	3.1	3.1
Ticagrelor	15	3.0	3.0
Mepolizumab	23	3.0	3.0
Axitinib	9	3.0	3.0
Canakinumab	5	3.0	3.0
Esketamine Hydrochloride	8	2.9	2.9
Fentanyl Citrate	8	2.9	2.9
Belimumab	14	2.9	2.9
Insulin Degludec	10	2.8	2.8
Tofacitinib	76	2.7	2.7
Acalabrutinib	5	2.7	2.7
Desvenlafaxine Succinate	11	2.6	2.6
Fam-Trastuzumab Deruxtecan-Nxki	4	2.6	2.6
Eltrombopag Olamine	9	2.5	2.5
Rifaximin	8	2.5	2.5
Vibegron	3	2.4	2.4
Inclisiran	3	2.4	2.4
Secukinumab	54	2.2	2.2
Naltrexone	10	2.1	2.1
Cariprazine	3	2.1	2.1
Paliperidone Palmitate	10	2.0	2.0
Hydrocodone Bitartrate	13	1.9	1.9
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	1.8	1.8
Olaparib	5	1.5	1.5
Voxelotor	4	1.2	1.2
Copper	5	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.